By Ananya Menon | Health & Pharma Correspondent
India's mood-drug market moved more money last year than the year before — 8.63% more. But it moved slightly fewer pills. Read those two numbers side by side and a growing market suddenly looks like something else: a country spending more on the same illness, without clear evidence that more people are getting well.
According to the market data reported, antidepressant and mood-drug sales in India reached Rs 2,842.1 crore in the 12 months ended September 2026, while unit sales declined 0.76%. The gap between those two directions is the story.
A Rs 2,842-Crore Bill, And 0.76% Fewer Strips
Value up, volume down is a familiar pattern in pharmaceutical data. It usually points to a change in what is being prescribed or bought — not a change in how many people are walking into a clinic.
If the same treatment is dispensed at a higher average cost, the market grows while the patient count stays flat. That is arithmetic, not necessarily progress.
Doctors quoted in the report were careful about exactly this. They said the Rs 2,842.1 crore figure cannot, on its own, be read as a measure of how many Indians are being treated for depression, anxiety or other mood disorders.
Why a Growing Market Can Be Bad News for Patients
For most industries, a rising market means more customers. In mental health, it can mean the opposite.
A growing bill with shrinking volumes raises three uncomfortable possibilities: people are being put on costlier medicines, people are being started on treatment and then dropping off, or a small group of patients is spending a lot more while a much larger group remains unmedicated altogether.
The data does not say which of these is happening. But the fact that it could be any of them is precisely why clinicians are wary of celebrating the headline number.
How This 12-Month Picture Came Together
Market figures such as these are drawn from the moving annual total — the trailing 12 months of sales recorded up to a fixed point, in this case September 2026.
That method smooths out seasonal spikes and gives a cleaner year-on-year comparison. It also means the number reflects what left the supply chain, not what was swallowed by a patient at the right dose, at the right time, for the right duration.
Between those two things sits the treatment gap — and it is where most of the clinical worry actually lives.
The People Behind the Number
A 29-year-old in a Tier-2 city who is prescribed a mood stabiliser has a very different experience from a 45-year-old in a metro paying out of pocket for a branded version of the same drug.
For the first patient, the barrier is often stigma, distance and the cost of a follow-up visit. For the second, it is the fear of being seen buying the strip.
Neither of them appears anywhere in a Rs 2,842.1 crore total. That is the limitation of market data in mental health: it counts rupees, and it counts strips, but it does not count recovery.
What Doctors Are Flagging Right Now
The clinicians quoted in the report raised three issues that sit outside the sales column altogether.
The first is unmet treatment need — the large pool of people who meet the criteria for a mood disorder but never reach a psychiatrist or even a primary-care doctor.
The second is changing prescribing patterns: what gets written at the first consultation has shifted over time, and that shift alone can move a market's value without moving its volume.
The third is adherence. A prescription that is filled once and never refilled generates revenue for exactly one month and no clinical benefit at all.
The Two Habits Quietly Reshaping Demand
Doctors also pointed to self-diagnosis and adherence as growing concerns — and these two behave very differently in the data.
Self-diagnosis pulls people into the market who may not need pharmacological treatment, sometimes after a few online searches or a friend's leftover strip. It can inflate volumes without improving outcomes.
Poor adherence does the reverse. It inflates the initial prescription count while quietly removing the patients who most needed to stay on treatment. Someone who stops after six weeks is a sale in the ledger and a relapse in the clinic.
Together, they help explain how a market can grow in rupees while the number of treated patients barely moves.
Confirmed, And Still Unclear
Confirmed: the market value rose 8.63% to Rs 2,842.1 crore for the 12 months ended September 2026, and unit sales declined 0.76%. Those are the reported figures for that window.
Unclear: which specific medicines or price segments drove the value growth, whether the fall in volumes reflects fewer new patients or more treatment drop-offs, and how much of the total comes from out-of-pocket spending versus institutional and insurance-backed purchase.
Also unverified: any assumption that 8.63% growth equals 8.63% more Indians in treatment. No data in the report supports that reading, and doctors quoted in it explicitly cautioned against it.
A note on sourcing: this report rests on the market figures and clinician observations as stated in the original brief. No independent regulatory filing or government dataset was available to corroborate the numbers, and readers should treat them as market-tracking estimates rather than official statistics.
Where the Optimistic Reading Could Still Fail
There is a fair counter-argument. Rising value could simply mean better-quality prescribing — newer, better-tolerated drugs that cost more but keep patients in treatment longer and with fewer side effects.
On that reading, the market is maturing rather than inflating.
But three risks cut against it. Price-led growth can reverse quickly if regulators act on affordability. Volume decline can deepen if generic substitution picks up. And any surge in self-medication tends to produce headlines and crackdowns, not better outcomes.
None of these are certain. All of them are live.
India's Mental Health Question Is Bigger Than One Market Figure
What the Rs 2,842.1 crore number really captures is a system in transition — one where demand is becoming visible faster than the supply of psychiatrists, counsellors and affordable follow-up care can absorb it.
That mismatch is not unique to antidepressants. It is the same pattern visible across diabetes, hypertension and other chronic conditions where the medicine is available but long-term management is not.
Mental health just makes the gap harder to ignore, because the treatment depends on a conversation that has to be repeated every month, not a one-time purchase.
If You or Someone You Know Is on These Medicines
Do not start, stop or change a psychiatric medicine on your own, and do not do it on the basis of a friend's prescription, an online quiz or a viral reel. These drugs work on timelines measured in weeks, and stopping abruptly can cause withdrawal effects as well as relapse.
If cost is the barrier, ask the prescribing doctor about generic options and public-sector supply. If side effects are the problem, report them — that is a treatment decision, not a personal failure.
For anyone in distress, India runs a national tele-mental health service, Tele-MANAS, which offers free counselling over phone and video. It is a starting point, not a substitute for a psychiatrist.
What to Watch Over the Next 12 Months
The clearest signal of genuine progress would be value growth accompanied by volume growth, not a falling unit count.
Watch three things: whether unit sales recover, whether out-of-pocket dependence declines, and whether adherence and self-diagnosis get addressed in formal clinical or public-health guidance rather than only in commentary.
If the market keeps growing while volumes keep shrinking, the honest conclusion will be that India is paying more for mental health — not that it is getting better at it.
Our Take
A Rs 2,842.1 crore market is not, by itself, a good or bad thing. It is a mirror. It shows a country finally buying medicine for an illness it spent decades whispering about — and simultaneously shows how little we know about whether that medicine is being taken correctly, for long enough, by the people who need it most.
The number that matters is not 8.63%. It is the gap between how many Indians need treatment and how many finish it.
Frequently Asked Questions
How much did India's antidepressant market grow?
The antidepressant and mood-drug market in India grew 8.63% to Rs 2,842.1 crore in the 12 months ended September 2026, according to the reported market figures. That is a value increase in rupees.
If sales grew, does that mean more Indians are getting treated?
Not necessarily. Unit sales fell 0.76% over the same period. A market can expand in value through higher-priced prescriptions, changed treatment patterns or price increases — without any rise in the number of patients being treated.
Why are doctors cautious about self-diagnosing depression?
Because mood disorders share symptoms with thyroid problems, anaemia, substance use and normal grief. A self-directed diagnosis can lead to the wrong medicine, the wrong dose, or unnecessary medication — while the real condition goes untreated.
What should someone do if they cannot afford ongoing psychiatric treatment?
Ask the doctor about generic alternatives and public-sector supply, check whether a government hospital or medical college near you runs an outpatient psychiatry clinic, and use Tele-MANAS for free counselling support. Do not stop prescribed medication without medical advice.
